drugset / Trial / NCT06317350

Clinical Study to Evaluate the Efficacy and Safety of GNS-212-E in Bowel Preparation for Colonoscopy

NCT06317350 ↗

Phase 3 Completed 318 enrolled Gunkang Pharmaceuticals, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a prospective, randomized, single-blind, parallel, active-controlled, and multi-center Phase III clinical trial.

Timeline

Start
2024-03-11
Primary completion
2024-10-16
Completion
2024-10-16

Drugs

EvaluationDrugModalityDoseRoute
Subject GNS-212-E1 Unknown — —
Subject GNS-212-E2 Unknown — —
Comparator GNS-212-ER Unknown — —

Indications

No indication recorded.